Boehringer launches hub for patient experience data
Boehringer Ingelheim has launched a hub to help patient organisations gather and use patient experience data (PED) more effectively.
NICE finally backs Enhertu for HER2-low breast cancer
Almost three years after Enhertu was made available in Scotland, the drug is finally an option for patients in England with HER2-low breast cancer.
Novo taps Anthropic's Claude AI for drug discovery
Novo adds Anthropic AI models and Claude Science to its drug discovery toolkit in a bid to become "the world's most AI-driven healthcare company."
Wales takes UK lead on needle-free anaphylaxis prevention
Wales has recommended ALK's EURneffy nasal spray as a needle-free option for emergency treatment of severe allergic reactions, including anaphylaxis.
Legend Biotech names ex-Novartis exec as CEO
Cell therapy developer Legend Biotech has named Ingrid Zhang as its new chief executive, ending its search for new leadership.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
RNA-Targeted Small Molecules: From Discovery to Clinic
Leading pharma, biotech and academic experts discuss the future of RNA therapeutics.
Novel CNS Biomarkers Summit Europe
Europe is rapidly becoming a hub for next-generation CNS biomarker innovation
Who's Speaking at the DIA-MHRA Global Summit 2026?
See who's speaking when regulators and industry convene at the DIA-MHRA Global Summit
4th Cell Therapy for Autoimmune Disease Summit
Developers are racing to overcome challenges around safety, scalability, durability of response, and patient access
10th Complement-Based Drug Development Summit
Uniting leaders pioneering complement-targeted therapies across ophthalmology, neurodegeneration, nephrology, oncology and autoimmune indications